Question

Difficulty: MediumGeneral Internal Medicine

A 54-year-old female patient is seen during morning rounds on the inpatient medical ward following 48 hours of treatment. She was initially admitted for a high fever, productive cough, and right-sided pleuritic chest discomfort. At the time of admission, a chest radiograph demonstrated a dense consolidation in the right lower lobe, prompting empiric therapy with intravenous ceftriaxone and oral azithromycin. Her past medical history is notable for chronic obstructive pulmonary disease.

This morning, the patient reports significant symptomatic improvement and is tolerating an oral diet. Vital signs demonstrate a temperature of 37.1°C (98.8°F), blood pressure of 124/80 mmHg, heart rate of 76/min, and a respiratory rate of 16/min with an oxygen saturation of 98% on room air. Pulmonary auscultation reveals decreased breath sounds at the right lung base but no wheezing or rhonchi.

The hospital laboratory reports that the sputum culture collected upon admission has grown *Streptococcus pneumoniae*. The antimicrobial susceptibility profile is as follows:

AntimicrobialInterpretation
PenicillinSusceptible
AmoxicillinSusceptible
CeftriaxoneSusceptible
LevofloxacinSusceptible
VancomycinSusceptible
AzithromycinResistant

Which of the following is the most appropriate next step in this patient's pharmacologic management?

  1. Transition to oral amoxicillinAnswer
  2. B
    Transition to oral levofloxacin
  3. C
    Transition to oral amoxicillin-clavulanate
  4. D
    Continue intravenous ceftriaxone to complete a 7-day course
  5. E
    Transition to oral azithromycin and initiate systemic corticosteroids

Answer

Transition to oral amoxicillin
The correct course of action is to transition the patient to oral amoxicillin. This patient was appropriately initiated on empiric intravenous antibiotics for community-acquired pneumonia. She is now clinically stable, afebrile, and tolerating an oral diet, satisfying all criteria for an intravenous-to-oral medication transition. Culture data confirms the pathogen is *Streptococcus pneumoniae* that is fully susceptible to penicillins. According to strict antimicrobial stewardship guidelines, therapy must be de-escalated to the narrowest-spectrum and most targeted agent available. High-dose oral amoxicillin provides excellent bioavailability and targeted coverage for penicillin-susceptible pneumococcal pneumonia, minimizing the risk of adverse effects.

Step-by-Step Solution

1
Evaluate the patient's clinical trajectory and criteria for oral transition.
The patient is clinically stable, afebrile for 24 hours, and tolerating oral intake.
Establishing clinical stability confirms the patient is ready to step down from intravenous to oral therapy, allowing for hospital discharge.
2
Analyze the microbiological data to identify the causative organism and vulnerabilities.
Sputum culture confirms *Streptococcus pneumoniae* that is susceptible to narrow-spectrum beta-lactams (penicillin, amoxicillin) but resistant to macrolides.
Definitive culture data allows the provider to transition from broad-spectrum empiric therapy to targeted therapy.
3
Select the optimal definitive pharmacotherapy.
Oral amoxicillin monotherapy is selected.
Antimicrobial stewardship dictates utilizing the narrowest-spectrum, effective oral agent to minimize collateral damage, reduce resistance, and limit side effects.

Key Concept

Antimicrobial stewardship in community-acquired pneumonia requires de-escalating from broad-spectrum intravenous therapy to targeted, narrow-spectrum oral therapy once the patient is clinically stable and specific susceptibility data is available.
Rate this question